^{Gilead Sciences, Inc. (USA) presented on August, 2020, the results of the phase 2b trial for NASH cirrhosis at EASL ~The Digital International Liver Congress™ 2020 ~.}

For detailed information, see the below URL.

https://ilc-congress.eu/wp-content/uploads/2020/08/digital-ilc-2020-abstract-book-20-august.pdf

Improvement of NASH cirrhosis has been reported by combination of cirofexor (FXR agonist) and firsocostat (ACC inhibitor). 

Combination therapy of test substances with different mechanisms of action could become the mainstream development policy for NASH therapeutics in the future.